Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl) methanamines as potent and efficacious type II calcimimetics

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6535-6538

  Poon, Steve F ^a   St Jean Jr , David J ^a   Harrington, Paul E ^a   Henley III, Charles ^a   Davis, James ^a   Morony, Sean ^a   Lott, Fred D ^a   Reagan, Jeff D ^a   Lu, Jenny Ying Lin ^a   Yang, Yuhua ^a   Fotsch, Christopher ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 PHENYL 1H PYRAZOL 3 YL)METHANAMINE DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR; METHYLAMINE; PYRAZOLE DERIVATIVE; R 568; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; RAT; SECONDARY HYPERPARATHYROIDISM; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; METHYLAMINES; MOLECULAR STRUCTURE; PARATHYROID HORMONE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049141764     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9012278     Document Type: Article

References (22)

1. Rodriguez, M.; Nemeth, E.; Martin, D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am. J. Physiol.: Renal Physiol. 2005, 288, F253-F264.
2. Skorecki, K.; Green, J.; Brenner, B. M. In Harrison's Principles of Internal Medicine, 16th ed.; Kaspar, D. L., Braunwald, E., Fauci, A. S., Hauser, S. L., Longo, D. L., Jameson, J. L., Eds.; McGraw-Hill: New York, 2005; Vol.261, pp 1653-1663.
3. Slatopolosky, E.; Brown, A.; Dusso, A. Pathogenesis of secondary hyperparathyroidism. Kidney Int., Suppl. 1999, 73, S14-S19.
4. 2+-sensing receptor from bovine parathyroid. Nature 1993, 366, 575-579.
5. Brown, E. M.; MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81, 239-297.
6. 2+ and a positive allosteric modulator. J. Biol. Chem. 2002, 277, 46622-46631.
7. Bai, M. Structure and function of the extracellular calcium-sensing receptors. Int. J. Mol. Med. 1999, 4, 115-125.
8. 2+-sensing receptor. J. Biol. Chem. 1996, 271, 5972-5975.
9. Hebert, S. C. Therapeutic use of calcimimetics. Annu. Rev. Med. 2006, 57, 349-364.
10. Harrington, P. E.; Fotsch, C. Calcium sensing receptor activators: calcimimetics. Curr. Med. Chem. 2007, 14, 3027-3034.
11. Wu, W.-N.; McKown, L. A.; Rybczynski, P. J.; Demarest, K. J. Hepatic biotransformation of the new calcium-mimetic agent, RWJ-68025, in the rat and in man - API-MS/MS identification of metabolites. J. Pharm. Pharmacol. 2003, 55, 631-637.
12. 2-(1-aryl)ethyl-3-phenylpropane-1,2- diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2000, 10, 2001-2004.
13. 1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1, 2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2004, 14, 3345-3349.
14. Balfour, J. A. B.; Scott, L. J. Drugs 2005, 65, 271-281.
15. Nemeth, E. F.; Steffey, M. E.; Hammerland, L. G.; Hung, B. C. P.; Van Wagenen, B. C.; Del Mar, E. G.; Balandrin, M. F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4040-4045.
16. Antonsen, J. E.; Sherrard, D. J.; Andress, D. L. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int. 1998, 53, 223-227.
17. Frazão, J. M.; Martins, P.; Coburn, J. W. The calcimimetic agents: perspectives for treatment. Kidney Int. 2002, 61, S149-S154.
18. Veber, D. F; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailabilty of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
19. Bringmann, G.; Geisler, J. P. Enantiomerically pure oxygenated 1-phenylethylamines from substituted acetophenones: by reductive amination and regiospecific benzylic cleavage. Tetrahedron Lett. 1989, 30, 317-320.
20. In a closely related series, the (R,R)-diastereomer was shown to be the more active epimer (data not shown).
21. Holzer, W.; Plagens, B.; Lorenz, K. Alkylation of pyrazolones via the Mitsunobu reaction. Heterocycles 1997, 45, 309-314. (Pubitemid 127689927)
22. The PD of cinacalcet in normal rats has been reported: Nemeth, E. F.; Heaton, W. H.; Miller, M.; Fox, J.; Balandrin, M. F.; Van Wagenen, B. C.; Colloton, M.; Karbon, W.; Scherrer, J.; Shatzen, E.; Rishton, G.; Scully, S.; Qi, M.; Harris, R.; Lacey, D.; Martin, D. Pharmacodynamics of the type II calcimimetic compound cinacalcet. J. Pharmacol. Exp. Ther. 2004, 308, 627-635.